Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non-small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study. Neal, J. W., Santoro, A., Viteri, S., Aix, S., Fang, B., Lim, F., Gentzler, R. D., Goldschmidt, J. H., Khrizman, P., Massarelli, E., Patel, S. B., Puri, S., Sudhagoni, R., Scheffold, C., Curran, D., Felip, E. LIPPINCOTT WILLIAMS & WILKINS. 2022

View details for Web of Science ID 000863680302196